FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         	UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  	OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5	
                      	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	                      	

1. Name and Address of Reporting Person *

FRAZIER KENNETH C	2. Issuer Name and Ticker or Trading Symbol

Merck & Co., Inc. [ MRK ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Executive Chair	
(Last)          (First)          (Middle)

MERCK & CO., INC., 126 E. LINCOLN AVENUE	3. Date of Earliest Transaction (MM/DD/YYYY)

11/1/2022		
(Street)

RAHWAY, NJ 07065
(City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)

 	6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned	
1.Title of Security
(Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code
(Instr. 8)	4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	V	Amount	(A) or (D)	Price				
Common Stock 	11/1/2022 	 	M	  	300000 	A	$0 	1006283.063 	D 	 	
Common Stock 	11/1/2022 	 	S	  	202319 	D	$99.6065 (1)	803964.063 	D 	 	
Common Stock 	11/1/2022 	 	S	  	96981 	D	$100.2242 (2)	706983.063 	D 	 	
Common Stock 	11/1/2022 	 	S	  	700 	D	$101.0471 (3)	706283.063 	D 	 	
Common Stock 	11/1/2022 	 	G	  V	1710 	D	$0 	704573.063 	D 	 	
Common Stock 	11/1/2022 	 	G	  V	2450 	D	$0 	702123.063 	D 	 	
Common Stock 	11/1/2022 	 	G	  V	1470 	D	$0 	700653.063 	D 	 	
Common Stock 	11/2/2022 	 	M	  	165828 	A	$0 	866481.063 	D 	 	
Common Stock 	11/2/2022 	 	M	  	134172 	A	$0 	1000653.063 	D 	 	
Common Stock 	11/2/2022 	 	S	  	205661 	D	$99.6791 (4)	794992.063 	D 	 	
Common Stock 	11/2/2022 	 	S	  	94339 	D	$100.4011 (5)	700653.063 (6)	D 	 	
Common Stock - 401(k) Plan 	 	 	 	  	 	 	 	4481.1286 (7)	I 	By 401(k) 	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)	
1. Title of Derivate Security
(Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code
(Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date	7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)	8. Price of Derivative Security
(Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to Buy) 	$58.08 	11/1/2022 	 	M 	  	  	300000  	5/1/2016 (8)	4/30/2025 	Common Stock 	300000 	$0 	165828 	D 	 	
Stock Option (Right to Buy) 	$58.08 	11/2/2022 	 	M 	  	  	165828  	5/1/2016 (8)	4/30/2025 	Common Stock 	165828 	$0 	0 	D 	 	
Stock Option (Right to Buy) 	$53.06 (9)	11/2/2022 	 	M 	  	  	134172  	5/10/2017 (10)	5/9/2026 	Common Stock 	134172 	$0 	705769 (9)	D 	 	

Explanation of Responses:	
(1) 	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.9700 to $99.9700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.	
(2) 	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.9800 to $100.9800, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.	
(3) 	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.0300 to $101.0700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.	
(4) 	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.0000 to $100.0000, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.	
(5) 	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.0100 to $101.0100, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.	
(6) 	Holdings include shares acquired in dividend reinvestment transactions.	
(7) 	Includes shares acquired and dividends earned through October 7, 2022 in the Merck U.S. Savings Plan, a 401(k) plan.	
(8) 	The option became exercisable in equal installments on 5/1/2016, 5/1/2017 and 5/1/2018.	
(9) 	Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.	
(10) 	The option became exercisable in equal installments on 5/10/2017, 5/10/2018 and 5/10/2019.	

Reporting Owners	
Reporting Owner Name / Address	Relationships	
	Director	10% Owner	Officer	Other	
FRAZIER KENNETH C
MERCK & CO., INC.
126 E. LINCOLN AVENUE
RAHWAY, NJ 07065	X		Executive Chair		

Signatures		
/s/ Kelly E. W. Grez as Attorney-in-Fact for Kenneth C. Frazier		11/3/2022	
**Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.	
*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).	
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).	
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.	
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.